Adjuvant Abiraterone After Radical Radiotherapy for High-Risk Locally Advanced Prostate Cancer
Men with very high-risk M0 prostate cancer (defined as N1 disease or at least two risk factors among T3-T4, PSA >40 ng/mL, Gleason score 8-10) receiving radical radiotherapy should receive 24 months of abiraterone plus prednisone combined with 24-36 months of ADT. 1
Evidence Strength and Recommendation Grade
The 2023 ESMO guidelines provide a Level I, Grade B recommendation for this combination based on the updated STAMPEDE trial analysis 1. This represents the highest quality guideline evidence available, though notably neither the EMA nor FDA have approved abiraterone for use in M0 disease 1.
Key Supporting Data from STAMPEDE
The updated STAMPEDE phase III trial demonstrated compelling benefits in the very high-risk M0 population:
- Metastasis-free survival: HR 0.54 (95% CI 0.43-0.68, P = 3.2×10⁻¹⁰) 1
- Overall survival: HR 0.63 (95% CI 0.48-0.82, P = 0.0005) 1
A comprehensive meta-analysis of STAMPEDE data in 1,974 patients with high-risk non-metastatic disease showed 2:
- Metastasis-free survival: HR 0.53 (95% CI 0.44-0.64, p<0.0001)
- Overall survival: HR 0.60 (95% CI 0.48-0.73, p<0.0001)
- 6-year metastasis-free survival: 82% vs 69% (combination vs control)
- Prostate cancer-specific survival: HR 0.49 (95% CI 0.37-0.65, p<0.0001)
Treatment Protocol
Specific regimen 1:
- Abiraterone acetate 1000 mg daily (or 500 mg of fine-particle formulation)
- Prednisone 5 mg twice daily
- Duration: 24 months
- Combined with long-course ADT: 24-36 months
- Radiotherapy as per local guidelines (typically 74 Gy in 37 fractions or equivalent)
Safety Profile
Grade 3+ adverse events occurred in 37% of patients receiving abiraterone plus ADT versus 29% with ADT alone in the STAMPEDE abiraterone-only arm 2. The most common grade 3+ events were:
- Hypertension: 5% (vs 1% control) 2
- Elevated transaminases: 6% (vs <1% control) 2
- Lymphopenia: 14% in smaller phase II studies 3
Critical monitoring requirements:
- Blood pressure monitoring for hypertension
- Liver function tests for transaminitis
- Electrolytes for hypokalemia (17% incidence) 4
- Cardiac monitoring (atrial fibrillation in 4%) 4
Important Caveats
Off-label use: This indication remains off-label as FDA approval is limited to metastatic castration-resistant prostate cancer 5. The FDA label specifically states abiraterone is indicated "for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC)" 5, not for M0 disease.
Patient selection: The benefit is specifically established for very high-risk M0 disease. The definition requires either:
- N1 (node-positive) disease, OR
- At least 2 of: T3-T4, PSA >40 ng/mL, Gleason 8-10 1
Radiotherapy requirement: The STAMPEDE data mandated radiotherapy for node-negative patients and encouraged it for node-positive disease, with 85% receiving planned radiotherapy 2. This combination should not be extrapolated to patients not receiving definitive radiotherapy.
Practical Implementation
The NCCN 2025 guidelines 4 discuss abiraterone extensively for metastatic CRPC but do not include specific recommendations for the M0 adjuvant setting post-radiotherapy, highlighting the regulatory gap despite strong trial evidence.
When enzalutamide was added to abiraterone in STAMPEDE, no additional benefit was observed (interaction HR 1.02,95% CI 0.70-1.50, p=0.91) 2, so dual ARPI therapy is not recommended.